ReviewDisease markers2020
Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers.
Review in Disease markers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 87 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Effect of Dapagliflozin on Cardiac Remodeling in Post Myocardial Infarction Patients
Comparative Study Between the Effects of High Doses Rosuvastatin and Atorvastatin on Ventricular Remodeling in Patients With ST-Segment Elevation Myocardial Infarction
Open the trial in the graphWho cites it
87 citing papers in PubMed, 3 syntheses or guidelines pooled it, 151 citations in OpenAlex.
- Proteins targeting ischaemic-reperfusion injury and repair after myocardial infarction: a systematic literature review.Cardiovascular research · 2026Pooled it
- Aldosterone Blockade in Acute Myocardial Infarction: A Systematic Review and Meta-Analysis.Cardiovascular therapeutics · 2021Pooled it
- Impact of mesenchymal stem cell therapy on cardiac function and outcomes in acute myocardial infarction: A meta-analysis of clinical studies.Cell transplantationPooled it
- Comparative Study Between the Effects of High Doses of Rosuvastatin and Atorvastatin on Ventricular Remodeling in Patients with ST-Segment Elevation Myocardial Infarction.Cardiovascular drugs and therapy · 2025Trial
- Effect of Colchicine in reducing MMP-9, NOX2, and TGF- β1 after myocardial infarction.BMC cardiovascular disorders · 2023Trial
- Association of systemic inflammation with major adverse cardiovascular events in patients with acute myocardial infarction.American journal of preventive cardiology · 2026Article
- The Osaka Prognostic Score as a Novel Predictor of Contrast-Induced Nephropathy and In-Hospital Mortality in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.Acta Cardiologica Sinica · 2026Article
- Myocardial Fibrosis in Cardiovascular Disease: An Integrative Biomarker-Imaging Framework Linking Molecular Mechanisms to Structural Phenotypes.Journal of clinical medicine · 2026Review
- Plasma Atherogenic Index Predicts Malignant Arrhythmias in Non-STElevation Myocardial Infarction.The Eurasian journal of medicine · 2026Article
- Early Dapagliflozin and Melatonin Treatment Ameliorated LV Fibrosis via Suppressing TGF-β1/Smads and Activating Nrf2-ARE Signaling in MI Rodent.The Kaohsiung journal of medical sciences · 2026Article
- Exploration of the Potential Mechanism of Metal Ion Transport-Related Genes in Myocardial Infarction Based on Transcriptomics.Journal of cellular and molecular medicine · 2026Article
- Exploring Serum Biomarker Levels in Tetralogy of Fallot, Hypoplastic Left Heart Syndrome, and Healthy Children.Pediatric cardiology · 2026Article
- Advances in biomarkers for myocardial injury after non-cardiac surgery.Journal of anesthesia and translational medicine · 2026Review
- Tissue-engineered cardiac patches enriched with IGF1 modified mRNA alleviate myocardial infarction by enhancing cell survival and angiogenesis.Materials today. Bio · 2026Article
- Value of Color Doppler Echocardiography for Predicting Heart Failure After Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction.International journal of general medicine · 2026Article
- A composite model incorporating systemic inflammatory burden and GRACE score for enhanced identification of elevated myocardial stress in acute myocardial infarction: an exploratory analysis.Frontiers in cardiovascular medicine · 2026Article
- Attenuating effects of inflammatory pathway by prolonged left ventricular unloading after myocardial infarction in male rats.PloS one · 2026Article
- Is the use of anthracyclines implicated in myocardial injury? Investigating the cardio modulatory effects of naringenin and apocynin in doxorubicin-induced cardiotoxicity in rats.Toxicology reports · 2025Article
- Injectable sustained-release danshensu sodium-loaded nanoparticle hydrogel targets macrophages to improve myocardial microenvironment for myocardial infarction treatment.Bioactive materials · 2025Article
- Left Ventricular Remodeling After Myocardial Infarction-Pathophysiology, Diagnostic Approach and Management During Cardiac Rehabilitation.International journal of molecular sciences · 2025Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of heart failure (HF) due to cardiac remodelling after acute myocardial infarction (AMI) does not decrease regardless of implementation of new technologies supporting opening culprit coronary artery and solving of ischemia-relating stenosis with primary percutaneous coronary intervention (PCI). Numerous studies have examined the diagnostic and prognostic potencies of circulating cardiac biomarkers in acute coronary syndrome/AMI and heart failure after AMI, and even fewer have depicted the utility of biomarkers in AMI patients undergoing primary PCI. Although complete revascularization at early period of acute coronary syndrome/AMI is an established factor for improved short-term and long-term prognosis and lowered risk of cardiovascular (CV) complications, late adverse cardiac remodelling may be a major risk factor for one-year mortality and postponded heart failure manifestation after PCI with subsequent blood flow resolving in culprit coronary artery. The aim of the review was to focus an attention on circulating biomarker as a promising tool to stratify AMI patients at high risk of poor cardiac recovery and developing HF after successful PCI. The main consideration affects biomarkers of inflammation, biomechanical myocardial stress, cardiac injury and necrosis, fibrosis, endothelial dysfunction, and vascular reparation. Clinical utilities and predictive modalities of natriuretic peptides, cardiac troponins, galectin 3, soluble suppressor tumorogenicity-2, high-sensitive C-reactive protein, growth differential factor-15, midregional proadrenomedullin, noncoding RNAs, and other biomarkers for adverse cardiac remodelling are discussed in the review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.